Cargando…

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment

Dopamine agonists (DAs) have demonstrated efficacy for the treatment of Parkinson’s disease (PD) but are limited by adverse effects (AEs). DAs can vary considerably in their receptor subtype selectivity and affinity, chemical composition, receptor occupancy, and intrinsic activity on the receptor. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Isaacson, Stuart H., Hauser, Robert A., Pahwa, Rajesh, Gray, David, Duvvuri, Sridhar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366643/ https://www.ncbi.nlm.nih.gov/pubmed/37497384 http://dx.doi.org/10.1016/j.prdoa.2023.100212

Ejemplares similares

Phase 1 Parkinson’s Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated
por: Sohur, U. Shivraj, et al.
Publicado: (2018)

Dopamine D(1) Agonists: First Potential Treatment for Late-Stage Parkinson’s Disease
por: Lewis, Mechelle M., et al.
Publicado: (2023)

Voltage-Dependent Dopamine Potency at D(1)-Like Dopamine Receptors
por: Ågren, Richard, et al.
Publicado: (2020)

The treatment of Parkinson's disease with dopamine agonists
por: Konta, Brigitte, et al.
Publicado: (2008)

Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists
por: Pogorelov, Vladimir M., et al.
Publicado: (2023)

Dopamine Agonist Therapy in Advanced Parkinson’s Disease
por: Reichmann, Heinz
Publicado: (2009)

Successful treatment of dopamine dysregulation syndrome with dopamine D(2) partial agonist antipsychotic drug
por: Mizushima, Jin, et al.
Publicado: (2012)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
por: Liu, Xiaoshuang, et al.
Publicado: (2019)

Chronic exposure to dopamine agonists affects the integrity of striatal D(2) receptors in Parkinson's patients
por: Politis, Marios, et al.
Publicado: (2017)

Dopamine agonist monotherapy utilization in patients with Parkinson’s disease
por: Frazer, Monica, et al.
Publicado: (2022)

Potent and Subtype-Selective Dopamine D(2) Receptor Biased Partial Agonists Discovered via an Ugi-Based Approach
por: Mallo-Abreu, Ana, et al.
Publicado: (2021)

Pramipexole, a dopamine D3/D2 receptor-preferring agonist, attenuates reserpine-induced fibromyalgia-like model in mice
por: Martins, Carlos Pereira, et al.
Publicado: (2021)

Involvement of Dopamine D2 Receptors in Addictive-Like Behaviour for Acetaldehyde
por: Brancato, Anna, et al.
Publicado: (2014)

Dopamine suppresses persistent network activity via D(1)-like dopamine receptors in rat medial entorhinal cortex
por: Mayne, Elizabeth W, et al.
Publicado: (2013)

Causes and factors related to dopamine agonist withdrawal in Parkinson′s disease
por: Castro, Ester Suárez, et al.
Publicado: (2016)

Specificity of striatal dopamine D(1) system in humans: implications for clinical use of D(1) receptor-agonists in Parkinson's disease
por: Goto, Satoshi
Publicado: (2023)

Spatial Reversal Learning in Chronically Sensitized Rats and in Undrugged Sensitized Rats with Dopamine D2-Like Receptor Agonist Quinpirole
por: Hatalova, Hana, et al.
Publicado: (2014)

Agonist and Antagonist Effects of Aripiprazole on D(2)-Like Receptors Controlling Rat Brain Dopamine Synthesis Depend on the Dopaminergic Tone
por: Ma, Guo Fen, et al.
Publicado: (2015)

Dopamine D2-Subtype Receptors Outside the Blood-Brain Barrier Mediate Enhancement of Mesolimbic Dopamine Release and Conditioned Place Preference by Intravenous Dopamine
por: Obray, J. Daniel, et al.
Publicado: (2022)

Role of dopamine and selective dopamine receptor agonists on mouse ductus arteriosus tone and responsiveness
por: Crockett, Stacey L., et al.
Publicado: (2019)

Dopamine Agonists and Pathologic Behaviors
por: Kelley, Brendan J., et al.
Publicado: (2012)

Dopamine Agonists for Pituitary Adenomas
por: Cooper, Odelia, et al.
Publicado: (2018)

Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist
por: Zhang, Jinglin, et al.
Publicado: (2016)

Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease
por: Picillo, Marina, et al.
Publicado: (2020)

Dopamine Agonist-Associated Hiccup in Parkinson’s Disease: A Case Report
por: EMEKLİ, Ahmed Serkan, et al.
Publicado: (2019)

Dopamine Modulates Excitatory Synaptic Transmission by Activating Presynaptic D1-like Dopamine Receptors in the RA Projection Neurons of Zebra Finches
por: Wang, Songhua, et al.
Publicado: (2020)

The effects of dopamine and dopamine receptor agonists on the phototransduction cascade of frog rods
por: Nikolaeva, Darya A., et al.
Publicado: (2019)

The D2-like Dopamine Receptor Agonist Quinpirole Microinjected Into the Ventral Pallidum Dose-Dependently Inhibits the VTA and Induces Place Aversion
por: Peczely, Laszlo, et al.
Publicado: (2022)

Novel and Potent Dopamine D(2) Receptor Go-Protein Biased Agonists
por: Bonifazi, Alessandro, et al.
Publicado: (2019)

PMON169 D2R Expression in Dopamine-Agonist Resistant Prolactinomas
por: Levine, Alice, et al.
Publicado: (2022)

Dopamine D(2)-Like Receptors Modulate Unconditioned Fear: Role of the Inferior Colliculus
por: de Oliveira, Amanda Ribeiro, et al.
Publicado: (2014)

Spatial Reorganization of Putaminal Dopamine D(2)-Like Receptors in Cranial and Hand Dystonia
por: Black, Kevin J., et al.
Publicado: (2014)

The Dopamine Receptor D3 Regulates Lipopolysaccharide-Induced Depressive-Like Behavior in Mice
por: Wang, Jing, et al.
Publicado: (2018)

PM435. Targeting Functional Selectivity of the Dopamine D2 Receptor for Treatment of Schizophrenia-like Behaviors
por: Wetsel, William, et al.
Publicado: (2016)

Conscious perception and the modulatory role of dopamine: no effect of the dopamine D2 agonist cabergoline on visual masking, the attentional blink, and probabilistic discrimination
por: Boonstra, E.A, et al.
Publicado: (2020)

The Transfection of BDNF to Dopamine Neurons Potentiates the Effect of Dopamine D3 Receptor Agonist Recovering the Striatal Innervation, Dendritic Spines and Motor Behavior in an Aged Rat Model of Parkinson’s Disease
por: Razgado-Hernandez, Luis F., et al.
Publicado: (2015)

Enhanced Dopamine Transmission and Hyperactivity in the Dopamine Transporter Heterozygous Mice Lacking the D3 Dopamine Receptor
por: Sotnikova, Tatyana D., et al.
Publicado: (2020)

Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report
por: Costa, M.L., et al.
Publicado: (2022)

Haloperidol bound D(2) dopamine receptor structure inspired the discovery of subtype selective ligands
por: Fan, Luyu, et al.
Publicado: (2020)

Crystal structure of dopamine receptor D4 bound to the subtype selective ligand, L745870
por: Zhou, Ye, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_skb6mkr96npcaafnfbq6d824ij